*3.5. A Case of CR following Peptide Vaccination*

Patient 6 was a 33-year-old female diagnosed with diffuse astrocytoma (grade 2) four years prior. Her tumor was enlarged and removed twice, followed by treatment with TMZ and radiation therapy for the preceding 12 months. The pathological diagnosis was anaplastic oligoastrocytoma (grade 3, MGMT unmethylated, IDH mutant and no 1p19q codeletion). However, her tumor recurred and could not be removed as it was located in a functional area (Figure 2a). She was thus enrolled in our study. Her tumor decreased in size three months after vaccine initiation and disappeared nine months after enrollment (Figure 2b,c). Thirty-eight months after the initiation of peptide vaccination, the patient remains free of tumor recurrence.

**Figure 2.** Contrast-enhanced magnetic resonance images of Patient 6. (**a**) Tumor had recurred in a functional area; (**b**) tumor was decreased 3 months after enrollment; (**c**) tumor disappeared 9 months after enrollment.
